Optimal trough concentration of teicoplanin for the treatment of methicillin‐resistant Staphylococcus aureus infection: A systematic review and meta‐analysis.

What is known and objective: It has been recommended that the trough concentration (Cmin) of teicoplanin should be maintained at ≥20 μg/ml for difficult‐to‐treat complicated infections caused by methicillin‐resistant Staphylococcus aureus (MRSA). Conversely, Cmin of teicoplanin of at least 10 μg/ml...

Full description

Bibliographic Details
Published in:Journal of Clinical Pharmacy & Therapeutics Vol. 46; no. 3; pp. 622 - 633
Main Authors: Hanai, Yuki, Takahashi, Yoshiko, Niwa, Takashi, Mayumi, Toshihiko, Hamada, Yukihiro, Kimura, Toshimi, Matsumoto, Kazuaki, Fujii, Satoshi, Takesue, Yoshio
Format: meta analysis research systematic review tables/charts Journal Article
Published: Wiley-Blackwell Jun2021
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=150539927&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 150539927
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        02694727
        EV4
      jtl: Journal of Clinical Pharmacy & Therapeutics
      issn: 02694727
      maglogo: Y
    pubinfo:
      dt: Jun2021
      vid: 46
      iid: 3
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        150539927
        148512688
        150539927
        150539927
        10.1111/jcpt.13366
        150539927
      ppf: 622
      ppct: 11
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Optimal trough concentration of teicoplanin for the treatment of methicillin‐resistant Staphylococcus aureus infection: A systematic review and meta‐analysis.
      aug:
        au:
          Hanai, Yuki
          Takahashi, Yoshiko
          Niwa, Takashi
          Mayumi, Toshihiko
          Hamada, Yukihiro
          Kimura, Toshimi
          Matsumoto, Kazuaki
          Fujii, Satoshi
          Takesue, Yoshio
        affil: Department of Pharmacy, Toho University Omori Medical Center, Tokyo, Japan
      sug:
        subj:
          Peptides Blood
          Antibiotics Blood
          Peptides Therapeutic Use
          Antibiotics Therapeutic Use
          Methicillin-Resistant Staphylococcus Aureus
          Staphylococcal Infections Drug Therapy
          Drug Efficacy Evaluation
          Peptides Adverse Effects
          Antibiotics Adverse Effects
          Drug Monitoring Methods
          Human
          Systematic Review
          Meta Analysis
          PubMed
          Staphylococcal Infections Mortality
          Hepatotoxicity
          Nephrotoxicity
          Descriptive Statistics
          Odds Ratio
          Confidence Intervals
          Dose-Response Relationship, Drug
          Risk Assessment
          Peptides Administration and Dosage
          Antibiotics Administration and Dosage
      ab: What is known and objective: It has been recommended that the trough concentration (Cmin) of teicoplanin should be maintained at ≥20 μg/ml for difficult‐to‐treat complicated infections caused by methicillin‐resistant Staphylococcus aureus (MRSA). Conversely, Cmin of teicoplanin of at least 10 μg/ml is required for non‐complicated MRSA infections. Considering the low incidence of nephrotoxicity for teicoplanin, Cmin = 15–30 μg/ml has been suggested for most MRSA infections. Thus, we assessed the clinical efficacy and adverse effects of teicoplanin at this target Cmin. Methods: We searched electronic databases (PubMed, Cochrane Central Register of Controlled Trials and Ichushi‐Web) to identify eligible studies. Studies were included if they provided the incidence of treatment success, mortality in patients with MRSA infection, and/or hepatotoxicity and nephrotoxicity according to the Cmin range. Results and discussion: Four trials assessing clinical success (n = 299) and three studies assessing adverse effects (n = 546) were included. Cmin = 15–30 μg/ml significantly increased the probability of treatment success compared with Cmin < 15 μg/ml (odds ratio [OR] = 2.68, 95% confidence interval [CI] = 1.14–6.32, p = 0.02). The all‐cause mortality rate did not differ between the groups (OR = 0.46, 95% CI = 0.13–1.61, p = 0.22). Cmin = 15–30 μg/ml did not increase the risks of nephrotoxicity (OR = 0.91, 95% CI = 0.49–1.69, p = 0.76) or hepatotoxicity (OR = 0.67, 95% CI = 0.18–2.44, p = 0.54). What is new and conclusion: Teicoplanin therapy using a Cmin target of 15–30 μg/ml is likely to be associated with better clinical responses than Cmin < 15 μg/ml without increasing the risk of adverse effects.
      pubtype: Academic Journal
      doctype:
        meta analysis
        research
        systematic review
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N